Lantern Pharma Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LTRN research report →
Companywww.lanternpharma.com
Lantern Pharma Inc. , a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer.
- CEO
- Panna Sharma
- IPO
- 2020
- Employees
- 24
- HQ
- Dallas, TX, US
Price Chart
Valuation
- Market Cap
- $40.45M
- P/E
- -2.24
- P/S
- 0.00
- P/B
- 10.35
- EV/EBITDA
- -2.14
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -0.97%
- ROIC
- -473.92%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-17,119,438 · 17.62%
- EPS
- $-1.57 · 99.92%
- Op Income
- $-17,978,494
- FCF YoY
- 12.04%
Performance & Tape
- 52W High
- $5.74
- 52W Low
- $1.11
- 50D MA
- $2.24
- 200D MA
- $3.33
- Beta
- 2.10
- Avg Volume
- 654.04K
Get TickerSpark's AI analysis on LTRN
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 12, 26 | Schalop Lee Troy | buy | 48,544 |
| May 12, 26 | Schalop Lee Troy | buy | 48,544 |
| May 12, 26 | KEYSER D JEFFREY | buy | 48,544 |
| May 12, 26 | KEYSER D JEFFREY | buy | 48,544 |
| Jan 9, 26 | KEYSER D JEFFREY | other | 28,844 |
| Jan 9, 26 | KEYSER D JEFFREY | other | 25,000 |
| Jan 9, 26 | Maccecchini Maria-Luisa | other | 25,000 |
| Jan 9, 26 | Maccecchini Maria-Luisa | other | 21,152 |
| Jan 9, 26 | Chandru Vijay | other | 25,000 |
| Jan 9, 26 | Chandru Vijay | other | 17,307 |
Our LTRN Coverage
We haven't published any research on LTRN yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate LTRN Report →